— Two oral presentations will highlight Phase 2 results from the ASTX030-01 trial of oral azacitidine and cedazuridine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or acute myeloid leukemia and Phase 2 results from ASTX727-03 trial of low-dose oral decitabine and cedazuridine in patients with lower-risk myelodysplastic syndromes — New data from 15 company-sponsored […]

The Association of State and Territorial Health Officials (ASTHO) released its top five state public health policy issues for 2026, which provide expert analysis on legislative priorities that will shape public health in the coming year. ASTHO's annual Legislative Prospectus Series provides concise, evidence-based policy guidance for public health leaders, lawmakers, and other decision makers

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Holiday toy shopping can feel like a big task, especially as wish lists seem to get longer earlier each year. Lifestyle Expert and mom Anna De Souza conducted a satellite media tour in partnership with Target and D S Simon Media to help families find the best

(NYSE:AVTR), LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avantor, Inc. (“Avantor” or “the Company”) (NYSE: AVTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the

(NASDAQ:KURA),(TSE:4151.T), – 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R

(NasdaqGM:CRVS), Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights

100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) — March Biosciences (March Bio), an clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced positive interim clinical data from its ongoing Phase 2 trial of MB-105

AVTR Investors Have Opportunity to Lead Avantor, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire December 08, 2025 LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avantor, Inc. (“Avantor” or “the Company”) (NYSE: AVTR) for

Lifestyle Expert Anna De Souza Shares This Year's Top Toys and Trending Holiday Gift Ideas for Kids on YourUpdateTV Holiday Toy Must-Haves: The Expert's Guide with Picks from Target GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Holiday toy shopping can feel like a big task, especially as wish lists seem

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial GlobeNewswire December 08, 2025 Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL,